Jing Li1, Rong Fu2, Liping Yang3, Weiping Tu4. 1. Department of Hematology, Tianjin Medical University General HospitalTianjin 300052, China; Department of Hematology, Shangyu People's HospitalShangyu 312300, Shaoxing, Zhejiang, China. 2. Department of Hematology, Tianjin Medical University General Hospital Tianjin 300052, China. 3. Department of Hematology, Yuebei People's Hospital Shaoguan 512000, Guangdong, China. 4. Department of Hematology, Shangyu People's Hospital Shangyu 312300, Shaoxing, Zhejiang, China.
Abstract
BACKGROUND: Expression patterns of microRNAs in serum are involved in potentially biomarkers for various diseases. The aim of the study was to investigate the expression level of miR-21 in diffuse large B cell lymphoma (DLBCL) and its prognostic value. METHODS: Real-time quantitative polymerase chain reaction (qRT-PCR) was used to measure miR-21 levels in serum samples from 112 patients with DLBCL as well as in serum samples from 45 healthy controls. The associations between miR-21 expression and clinicopathologic parameters and overall survival of the patients, were analyzed by chi-square test and Kaplan-Meier method. The Cox proportional hazards regression analyses were performed to estimate the prognostic values for patient survival prediction. RESULTS: We found that serum miR-21 expression was markedly upregulated in patients with DLBCL than healthy controls. Increased miR-21 expression was significantly correlated with B symptoms, IPI score, CHOP-like treatment and Rituximab (all Ps<0.05). Moreover, DLBCL patients with miR-21 higher expression have shown significantly worse overall survival than those with lower miR-21 expression. And miR-21 expression was an independent prognostic marker of overall survival in a multivariate analysis (P=0.001, HR: 4.404, 95% CI: 1.770-10.956). CONCLUSION: The results of the present study suggested miR-21 expression level could be a novel potential biomarker for DLBCL prognosis.
BACKGROUND: Expression patterns of microRNAs in serum are involved in potentially biomarkers for various diseases. The aim of the study was to investigate the expression level of miR-21 in diffuse large B cell lymphoma (DLBCL) and its prognostic value. METHODS: Real-time quantitative polymerase chain reaction (qRT-PCR) was used to measure miR-21 levels in serum samples from 112 patients with DLBCL as well as in serum samples from 45 healthy controls. The associations between miR-21 expression and clinicopathologic parameters and overall survival of the patients, were analyzed by chi-square test and Kaplan-Meier method. The Cox proportional hazards regression analyses were performed to estimate the prognostic values for patient survival prediction. RESULTS: We found that serum miR-21 expression was markedly upregulated in patients with DLBCL than healthy controls. Increased miR-21 expression was significantly correlated with B symptoms, IPI score, CHOP-like treatment and Rituximab (all Ps<0.05). Moreover, DLBCL patients with miR-21 higher expression have shown significantly worse overall survival than those with lower miR-21 expression. And miR-21 expression was an independent prognostic marker of overall survival in a multivariate analysis (P=0.001, HR: 4.404, 95% CI: 1.770-10.956). CONCLUSION: The results of the present study suggested miR-21 expression level could be a novel potential biomarker for DLBCL prognosis.
Entities:
Keywords:
MicroRNA-21; diffuse large B-cell lymphoma; prognosis
Authors: Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt Journal: N Engl J Med Date: 2002-06-20 Impact factor: 91.245
Authors: N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter Journal: Blood Date: 1994-09-01 Impact factor: 22.113
Authors: Francesco Marchesi; Giulia Regazzo; Francesca Palombi; Irene Terrenato; Andrea Sacconi; Manuela Spagnuolo; Sara Donzelli; Mirella Marino; Cristiana Ercolani; Anna Di Benedetto; Giovanni Blandino; Gennaro Ciliberto; Andrea Mengarelli; Maria Giulia Rizzo Journal: J Exp Clin Cancer Res Date: 2018-05-02
Authors: Zhong Zheng; Peng-Peng Xu; Li Wang; Hui-Jin Zhao; Xiang-Qin Weng; Hui-Juan Zhong; Bin Qu; Jie Xiong; Yan Zhao; Xue-Feng Wang; Anne Janin; Wei-Li Zhao Journal: J Exp Clin Cancer Res Date: 2017-06-21
Authors: Cliff I Oduor; Mercedeh Movassagh; Yasin Kaymaz; Kiprotich Chelimo; Juliana Otieno; John M Ong'echa; Ann M Moormann; Jeffrey A Bailey Journal: Front Microbiol Date: 2017-03-28 Impact factor: 5.640
Authors: Maria Lopez-Santillan; Ane Larrabeiti-Etxebarria; Javier Arzuaga-Mendez; Elixabet Lopez-Lopez; Africa Garcia-Orad Journal: Oncotarget Date: 2018-04-27
Authors: Erika Larrea; Carla Sole; Lorea Manterola; Ibai Goicoechea; María Armesto; María Arestin; María M Caffarel; Angela M Araujo; María Araiz; Marta Fernandez-Mercado; Charles H Lawrie Journal: Int J Mol Sci Date: 2016-04-27 Impact factor: 5.923